“This exciting data is very reassuring and could impact a large number of patients with cancer who have very low chances of their breast cancer returning even without radiation therapy. These findings are the first of a number of recent trials in breast cancer looking at reducing treatments that are still commonly used but that may not be necessary for appropriately selected patients,” said Corey Wayne Speers, MD, PhD, ASCO Expert in radiation oncology.
CHICAGO — Based on guidance from biomarker screening, patients who are 55 years of age and older with low-grade luminal A-type breast cancer may only need endocrine therapy following breast conserving surgery and could avoid radiation therapy entirely, according to new research findings that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Study at a Glance
Omitting radiation therapy in treating luminal A-type breast cancer using biomarker screening guidance.
500 node-negative breast cancer patients in Canada who were 55 years of age or older with luminal A-type tumors (13.25% or less of tumors cells had the protein marker Ki67).
For patients who were treated with breast conserving surgery followed by endocrine therapy, but not radiation therapy, the:
The findings indicate there is a significant subset of patients with breast cancer who can avoid radiation therapy. This could be practice changing.
The LUMINA study enrolled participants whose biomarker screening results showed that 13.25% or less of the tumor cells had the protein marker, Ki67, which is associated with cancer cell proliferation and is consistent with the luminal A breast cancer subtype. Given a known lower risk of recurrence, patients underwent breast conserving surgery followed by endocrine therapy for five years; however, they did not receive radiation therapy. Five-year rates in the study were a:
- 2.3% chance of local recurrence, the primary outcome
- 1.9% chance of breast cancer developing in the opposite breast
- Recurrence-free survival rate of 97.3%
- Disease-free survival rate of 89.9%
- OS rate of 97.2%.
“Previous studies have shown that other tumor biomarkers can identify patients at very low risk of recurrence, thereby omitting chemotherapy as it is unlikely to offer benefit. The LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy, including significant acute and late side effects; such effects include fatigue and rare life-threatening side effects of cardiac disease and second cancers,” said lead author Timothy Joseph Whelan, MD, FASCO, professor in the Department of Oncology and Canada Research Chair in Breast Cancer Research at McMaster University, and a radiation oncologist at the Juravinski Cancer Centre in Hamilton, Ontario, Canada.
Low-grade breast cancer is usually slow growing and less likely to spread than high-grade cancer. Localized breast cancer represents 63% of all breast cancer cases and has a 90% or higher five-year survival rate. Regional breast cancer, which has spread to nearby lymph nodes, represents 29% of all breast cancer diagnoses and has a 75-85% five-year survival ratei.
Patients with a low-grade breast cancer diagnosis usually have the tumor surgically removed while maintaining the breast. Surgery is often followed by endocrine therapy to block or keep estrogen hormone levels low. Historically, these patients have undergone radiation therapy to reduce the risk of recurrence of the original tumor, but such therapy can be costly and may result in toxicity later in life. Also, with improved mammography and surgical techniques as well as effective endocrine therapy, the risk of local recurrence following breast conserving surgery has decreased in recent years.
A study that looked back at earlier cases of the disease found that women over age 60 with low-grade luminal A-type breast cancer who only received breast-conserving surgery had a low rate of local recurrence. Previous studies in women older than 70 years of age showed risk of local recurrence of about 4 to 5%. The LUMINA findings suggest that in luminal A breast cancer, the risk is lower, even in younger women between 55 and 75 years of age.
In 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in the United States. Luminal A is the most common subtype of breast cancer and represents 50-60% of all breast cancers diagnosed annuallyii.
About the Study
The single-arm prospective phase III LUMINA trial enrolled 500 patients from 26 centers in Canada who had a Ki67 tumor cell count of 13.25% or less. The patients had to be older than 55 years of age and have node-negative, grade 1 or 2 tumors smaller than two centimeters in size that had been removed by breast conserving surgery. Biopsy results had to show that the cancers were luminal A-type tumors. Participants were followed for a median of five years. The median age of the participants was 67 years and 88% of the patients were under 75 years of age.
Enrollees had breast conserving surgery for low-grade breast cancer, defined as the luminal A subtype, which is estrogen and progesterone receptor-positive, HER2-negative and they had a low Ki67 cell count. Patients were not offered radiation therapy. They were followed every six months for the first two years and then yearly.
The patients in the study will continue to be followed for up to 10 years for effects on long-term recurrence and survival.
LUMINA was sponsored by the Canadian Breast Cancer Foundation and the Canadian Cancer Society.
View the disclosures for ASCO’s Cancer Communications Committee: https://www.asco.org/sites/new-www.asco.org/files/content-files/about-asco/pdf/2022-asco-ccc-disclosures.pdf
For your readers:
- Guide to Breast Cancer
- Side Effects of Radiation Therapy
- Long-Term Side Effects of Cancer Treatment
- Cancer.Net Blog Post (English)
ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL COVERAGE.
[i] Cancer Stat Facts: Female Breast Cancer: https://seer.cancer.gov/statfacts/html/breast.html
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.